CBIO

Crescent Biopharma
CBIO

Overview Fund Trends Analyst Outlook Journalist POV

34 hedge funds and large institutions have $14.3M invested in Crescent Biopharma in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

less first-time investments, than exits

New positions opened: | Existing positions closed:

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
34
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$6K
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$18K
2
+$17.8K
3
+$10K
4
UBS Group
UBS Group
Switzerland
+$10K
5
TRCT
Tower Research Capital (TRC)
New York
+$6.67K

Top Sellers

1
-$112K
2
-$60.9K
3
-$51.9K
4
Millennium Management
Millennium Management
New York
-$37.7K
5
Charles Schwab
Charles Schwab
California
-$37K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$5K
27
$3K
28
$2K
29
$1K
30
$265
31
–
32
–
33
–
34
–
35
–
1
2